Liangang Liu

发表

Drug‐Drug Interaction Study to Assess the Effect of Cytochrome P450 Inhibition and Induction on the Pharmacokinetics of the Novel Cereblon Modulator Avadomide (CC‐122) in Healthy Adult Subjects

S. Zhou, M. Palmisano, K. Ogasawara, 2019, Journal of clinical pharmacology.

The effects of apremilast on the QTc interval in healthy male volunteers: a formal, thorough QT study

Mahmoud S. Assaf, Y. Liu, S. Zhou, 2016, International journal of clinical pharmacology and therapeutics.

In Vivo Assessment of the Effect of CYP1A2 Inhibition and Induction on Pomalidomide Pharmacokinetics in Healthy Subjects

S. Zhou, M. Palmisano, Chengyue Zhang, 2018, Journal of clinical pharmacology.

Evaluation of CYP3A‐mediated drug–drug interactions with romidepsin in patients with advanced cancer

Suzanne F. Jones, H. Burris, J. Infante, 2015, Journal of clinical pharmacology.

Effects of strong and moderate CYP3A4 inducers on the pharmacokinetics of fedratinib in healthy adult participants

S. Surapaneni, S. Zhou, M. Palmisano, 2021, Cancer Chemotherapy and Pharmacology.

A Phase I Study in Patients with Solid or Hematologic Malignancies of the Dose Proportionality of Subcutaneous Azacitidine and Its Pharmacokinetics in Patients with Severe Renal Impairment

A. Mita, N. Gabrail, S. Goel, 2014, Pharmacotherapy.

First‐in‐Human, Single‐ and Multiple‐Ascending‐Dose Studies in Healthy Subjects to Assess Pharmacokinetics, Pharmacodynamics, and Safety/Tolerability of Iberdomide, a Novel Cereblon E3 Ligase Modulator

M. Palmisano, P. Schafer, Ying Ye, 2020, Clinical pharmacology in drug development.

Evaluation of iberdomide and cytochrome p450 drug-drug interaction potential in vitro and in a phase 1 study in healthy subjects

S. Surapaneni, M. Palmisano, Ying Ye, 2020, European Journal of Clinical Pharmacology.

Population Pharmacokinetics of Pomalidomide

Yejun Xu, S. Zhou, M. Palmisano, 2015, Journal of clinical pharmacology.

A Phase I, open-label, randomized, crossover study in healthy subjects to evaluate the bioavailability of, and the food effect on, a pomalidomide oral liquid suspension

S. Zhou, M. Palmisano, Liangang Liu, 2018, Clinical pharmacology : advances and applications.

Pharmacokinetics and safety of Enasidenib following single oral doses in Japanese and Caucasian subjects

S. Zhou, M. Palmisano, Liangang Liu, 2018, Pharmacology research & perspectives.

Effect of fluconazole on the pharmacokinetics of a single dose of fedratinib in healthy adults

S. Surapaneni, S. Zhou, M. Palmisano, 2022, Cancer Chemotherapy and Pharmacology.

An open‐label, phase 1, randomized, three treatments, three‐period, crossover, relative bioavailability study of CC‐292, a potent and orally available inhibitor of bruton tyrosine kinase

S. Zhou, Liangang Liu, Yan Li, 2022, Journal of clinical pharmacy and therapeutics.

Lenalidomide at Therapeutic and Supratherapeutic Doses Does Not Prolong QTc Intervals in the Thorough QTc Study Conducted in Healthy Men

Mahmoud S. Assaf, S. Zhou, M. Palmisano, 2013, Basic & clinical pharmacology & toxicology.

An Open Label, Phase 1, Randomized, Seven-treatment, Seven-period, Crossover Study to Assess the Relative Bioavailability, pH Effect, Food Effect, and Dose Proportionality of CC-292, a Potent and Orally Available Bruton’s Tyrosine Kinase Inhibitor

S. Zhou, Liangang Liu, Yan Li, 2022, European Journal of Drug Metabolism and Pharmacokinetics.

Pharmacokinetics and tolerability of apremilast in healthy Korean adult men

Howard Lee, M. Palmisano, F. Ramírez-Valle, 2021, Clinical and translational science.

Pharmacokinetics and safety of apremilast (CC-10004) in subjects with hepatic impairment

Liangang Liu, Richard A. Preston, Mahmoud S. Assaf, 2014, Int. J. Medical Eng. Informatics.

Safety, Pharmacokinetics, and Pharmacodynamics of CC‐90001 (BMS‐986360), a c‐Jun N‐terminal Kinase Inhibitor, in Phase 1 Studies in Healthy Participants

D. Tatosian, Atalanta Ghosh, M. Palmisano, 2022, Clinical pharmacology in drug development.

An Open‐Label, Phase 1 Study to Assess the Effects of Hepatic Impairment on Pomalidomide Pharmacokinetics

S. Zhou, M. Palmisano, Liangang Liu, 2018, Clinical pharmacology in drug development.

Cereblon modulator iberdomide induces degradation of the transcription factors Ikaros and Aiolos: immunomodulation in healthy volunteers and relevance to systemic lupus erythematosus

R. Chopra, Lei Wu, J. Kosek, 2018, Annals of the rheumatic diseases.

Pomalidomide: Evaluation of cytochrome P450 and transporter‐mediated drug–drug interaction potential in vitro and in healthy subjects

Mahmoud S. Assaf, M. Palmisano, Liangang Liu, 2015, Journal of clinical pharmacology.

Single-Dose Pharmacokinetics of Ozanimod and its Major Active Metabolites Alone and in Combination with Gemfibrozil, Itraconazole, or Rifampin in Healthy Subjects: A Randomized, Parallel-Group, Open-Label Study

Peijin Zhang, Atalanta Ghosh, M. Palmisano, 2020, Advances in Therapy.

No clinically significant drug interactions between lenalidomide and P-glycoprotein substrates and inhibitors: results from controlled phase I studies in healthy volunteers

S. Zhou, M. Palmisano, Liangang Liu, 2014, Cancer Chemotherapy and Pharmacology.

Exposure‐Response Analysis to Assess the Concentration‐QTc Relationship of Iberdomide

S. Zhou, Liangang Liu, Yan Li, 2023, Clinical pharmacology in drug development.

Impact of fedratinib on the pharmacokinetics of transporter probe substrates using a cocktail approach

S. Surapaneni, S. Zhou, M. Palmisano, 2021, Cancer Chemotherapy and Pharmacology.

Safety, Pharmacokinetics, and Antifibrotic Activity of CC‐90001 (BMS‐986360), a c‐Jun N‐Terminal Kinase Inhibitor, in Pulmonary Fibrosis

M. Palmisano, G. Horan, F. Ramírez-Valle, 2023, Clinical pharmacology in drug development.

Single‐Dose Pharmacokinetics, Safety, and Tolerability of Avadomide (CC‐122) in Subjects With Mild, Moderate, or Severe Renal Impairment

S. Zhou, M. Palmisano, Kimberly MacGorman, 2019, Clinical pharmacology in drug development.

Distribution of pomalidomide into semen of healthy male subjects after multiple doses

S. Zhou, M. Palmisano, Liangang Liu, 2018, Clinical pharmacology : advances and applications.

A Phase 1, double-blind, 4-period crossover study to investigate the effects of pomalidomide on QT interval in healthy male subjects

Mahmoud S. Assaf, E. O'Mara, Liangang Liu, 2016, Cancer Chemotherapy and Pharmacology.

Pomalidomide: Evaluation of cytochrome P450 and transporter‐mediated drug–drug interaction potential in vitro and in healthy subjects

Mahmoud S. Assaf, M. Palmisano, Liangang Liu, 2015, Journal of clinical pharmacology.

Relative bioavailability of fedratinib through various alternative oral administration methods in healthy adults

Liangang Liu, Leon Carayannopoulos, Yongjun Xue, 2023, Cancer Chemotherapy and Pharmacology.